EAGAN, MN – May 4, 2007 – Biothera, a biotechnology company developing pharmaceuticals that prime the innate immune system and enhance drug efficacy, will present its clinical research at the BIO International Convention in Boston on May 6-9.
Steven J. Karel, Biothera’s chief of technology operations, will discuss the company’s novel technology and its applications in the areas of oncology, anti-infectives and hematopoiesis.
“Our technology has the potential to dramatically enhance both existing and developmental drug treatments for most major types of cancer,” said Daniel K. Conners, Biothera founder and chairman. “Our lead compound, Imprime PGG™, is a biological response modifier that enhances specific innate immune cell responses.”
Biothera has two active Investigational New Drug (IND) filings with the U.S. Food and Drug Administration. The company has completed:
- Two Phase I clinical trials with in support of its cancer IND for the use of Imprime PGG in combination with anti-cancer monoclonal antibodies.
- A Phase I/II trial with Imprime PGG in combination with a hematopoietic growth factor.
Biothera plans to initiate multiple Phase Ib and Phase II studies with Imprime PGG in combination with anti-cancer monoclonal antibodies.
Event Details
| Meeting: | BIO International Convention |
| Presenter: | Steven J. Karel Biothera Chief of Technology Operations |
| Date/Time: | Tuesday, May 8th at 2:15 pm |
| Location: | Boston Convention & Exhibition Center BIO Business Forum Level 1 of BCEC at the North Lobby |
Biothera will conduct individual meetings with corporate partner and licensing candidates during the convention. To schedule a meeting, contact Robert J. Brown, senior vice president, Corporate Development, at 651-675-0300 or at rbrown@biotherapharma.com.
About Biothera, the Immune Health Company
Biothera is a biotechnology company dedicated to improving immune health. The company's primary focus is developing pharmaceuticals that engage the innate immune system to fight cancer. Other applications include hematopoietic (white blood cell) recovery and infectious disease.
Contact:
David Walsh
VP, Communications
Biothera, the Immune Health Company
651-256-4606
dwalsh@biotherapharma.com